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Vaccinia virus (VACV) encodes many immunomodulatory proteins, including inhibitors of
apoptosis and modulators of innate immune signalling. VACV protein N1 is an intracellular
homodimer that contributes to virus virulence and was reported to inhibit nuclear factor (NF)-kB
signalling. However, analysis of NF-kB signalling in cells infected with recombinant viruses with or
without the N1L gene showed no difference in NF-kB-dependent gene expression. Given that
N1 promotes virus virulence, other possible functions of N1 were investigated and this revealed
that N1 is an inhibitor of apoptosis in cells transfected with the N1L gene and in the context
of VACV infection. In support of this finding virally expressed N1 co-precipitated with endogenous
pro-apoptotic Bcl-2 proteins Bid, Bad and Bax as well as with Bad and Bax expressed by
transfection. In addition, the crystal structure of N1 was solved to 2.9 A˚ resolution (0.29 nm).
Remarkably, although N1 shows no sequence similarity to cellular proteins, its three-dimensional
structure closely resembles Bcl-xL and other members of the Bcl-2 protein family. The structure
also reveals that N1 has a constitutively open surface groove similar to the grooves of other
anti-apoptotic Bcl-2 proteins, which bind the BH3 motifs of pro-apoptotic Bcl-2 family members.
Molecular modelling of BH3 peptides into the N1 surface groove, together with analysis of their
physico-chemical properties, suggests a mechanism for the specificity of peptide recognition.
This study illustrates the importance of the evolutionary conservation of structure, rather than
sequence, in protein function and reveals a novel anti-apoptotic protein from orthopoxviruses.
INTRODUCTION
Apoptosis represents an important host-innate immune
response to infection and aids elimination of virus-infected
cells (Roulston et al., 1999). The B-cell lymphoma protein-
2 (Bcl-2) family regulates the release of pro-apoptotic
molecules from mitochondria and includes both pro- and
anti-apoptotic members. These contain one or more
distinct Bcl-2 homology motifs (BH1–4) and, in some
cases, an additional C-terminal hydrophobic helix for
targeting the protein to intracellular membranes (Cory
et al., 2003). Anti-apoptotic members such as Bcl-xL, Bcl-2,
Bcl-w and Mcl-1 contain several BH motifs, whereas pro-
apoptotic members, such as Bak, Bax and Bok, may
contain multiple BH motifs, or may be BH3 ‘only’ such as
Bad, Bid, Bim, Hrk, Noxa and Puma (Cory et al., 2003).
The crystal structure of Bcl-xL and the nuclear magnetic
resonance structure of other anti-apoptotic Bcl-2 proteins
show a surface groove that binds BH3 motifs of pro-
apoptotic family members (Petros et al., 2004).
Apoptotic signalling pathways are evolutionarily conserved
in eukaryotes and Bcl-2 counterparts are present in Droso-
phila melanogaster, Caenorhabditis elegans and mammals.
During their evolution viruses have developed mechanisms
to block apoptosis, permitting completion of their replica-
tion cycle. Several DNA viruses encode anti-apoptotic
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Bcl-2-like proteins that were identified through the presence
of BH motifs in the primary amino acid sequence (Polster
et al., 2004). Bcl-2-like proteins are encoded by gammaher-
pesviruses Epstein–Barr virus (Hickish et al., 1994), Kaposi’s
sarcoma-associated herpesvirus (Sarid et al., 1997) and
murine gammaherpesvirus 68 (Virgin et al., 1997), by the
alphaherpesvirus Marek’s disease virus (Afonso et al., 2001)
and also by African swine fever virus (Neilan et al., 1993).
The genomes of orthopoxviruses such as VACV and variola
virus, the causative agent of smallpox do not encode proteins
with identifiable BH motifs. However, Bcl-2 counterparts
would perhaps be expected given that poxviruses encode
numerous immunomodulatory proteins, including serpins,
decoy receptors for interleukin (IL)-1b, interferon (IFN)-c,
IFN-b and tumour necrosis factor (TNF)-a (Seet et al., 2003),
and employ several anti-apoptotic strategies (for review see
Taylor & Barry, 2006). In addition, avipoxviruses such as
fowlpox and canarypox contain identifiable Mcl-1 counter-
parts (Afonso et al., 2000; Tulman et al., 2004), and the
VACV F1 protein displays the hallmarks of a functional
orthologue as it localizes to mitochondria, inhibits apop-
tosis and binds pro-apoptotic Bak (Wasilenko et al., 2005;
Fischer et al., 2006; Postigo et al., 2006).
The VACV protein N1 was first described as a secreted
protein (Kotwal et al., 1989) but was shown subsequently to
be a 14 kDa intracellular homodimer that is expressed early
in the virus life cycle and contributes to virus virulence in
mouse intradermal and intranasal models of infection
(Bartlett et al., 2002). Overexpression of N1 was reported
to inhibit NF-kB activation downstream of TNF, IL-1 and
Toll-like receptors (TLRs) in vitro, and this was suggested to
be through direct inhibition of the IkB kinase complex
(DiPerna et al., 2004). Here, we demonstrate that N1 is
an inhibitor of apoptosis. Cells expressing N1 following
transfection or virus infection were resistant to staurosporine
(ST)-induced apoptosis. Consistent with this, N1 in VACV-
infected cells co-precipitated the pro-apoptotic Bcl-2 family
proteins Bid, Bad and Bax. Lastly, the crystal structure of N1
was determined and showed compelling structural similarity
to Bcl-2 family members, although it lacks amino acid
sequence similarity to these proteins. The structure also
revealed that N1 contains a surface groove that resembles the
BH3-binding grooves of other Bcl-2 proteins. Molecular
modelling of BH3 peptides of pro-apoptotic Bcl-2 proteins
into the N1 groove suggests a mechanism for binding
specificity. These results reveal a Bcl-2-like protein in VACV
with anti-apoptotic activity and illustrate the importance of
structure in the determination of protein function. During
the preparation of this article, the crystal structure of N1 was
reported by another group who demonstrated that N1 bound
BH3 peptides from pro-apoptotic Bcl-2 family proteins Bid,
Bim and Bak in vitro (Aoyagi et al., 2007).
METHODS
Cells and viruses. BS-C-1 and HeLa cells were grown at 37 uC in a
5 % CO2 atmosphere in Dulbecco’s modified Eagle’s medium or
minimum essential medium (MEM), respectively, supplemented with
10 % heat-treated (56 uC, 1 h) fetal bovine serum (FBS; Invitrogen),
4 mM L-glutamine (Invitrogen), 100 U penicillin (Invitrogen) ml21
and 100 mg streptomycin (Invitrogen) ml21. HeLa cells were also
supplemented with MEM non-essential amino acid solution (Sigma-
Aldrich). VACV recombinants vN1, vDN1 and vN1-rev derived from
VACV strain Western Reserve (WR) were described previously
(Bartlett et al., 2002). Virus infectivity was titrated by plaque assay on
BS-C-1 cells.
Assay for NF-kB activation. HeLa cells were transfected with a
luciferase reporter plasmid, pNF B-Luc, containing NF-kB-binding
sites (Stratagene), reseeded and infected with VACV, vDN1 or vN1-
rev at 2 p.f.u. per cell for 2 h. Cells were then treated with 100 ng
human IL-1b (Peprotech) ml21 for 2 h and lysates were assayed by
the luciferase assay system as described by the manufacturer
(Promega). Luciferase activity was normalized to the total protein
content from the corresponding extract as a transfection efficiency
control. Data are expressed as the mean fold induction as a ratio to
the mean of the normalized luciferase activity in the mock infection.
Two duplicate experiments were carried out with samples in triplicate
(Student’s t-test; *P,0.05; **P,0.005).
Immunoprecipitation. HeLa cells were transfected with plasmids
expressing HA-tagged Bax, Bad or eiF4E control, and 24 h post-
transfection were infected with vN1 or vDN1 at 10 p.f.u. per cell
for 6 h. Alternatively, for immunoprecipitation of endogenous Bcl-2
proteins, HeLa cells were infected for 6 h as above. Monolayers were
washed twice in PBS. For analysis of N1 interaction with Bad and Bax
expressed by transfection, cells were lysed in CHAPS buffer [100 mM
NaCl, 10 mM Tris, pH 7.5, 10 % (w/v) glycerol, 1 % CHAPS, 1 mM
MgCl2, 1 mM EDTA and 16 protease inhibitor tablet (Roche)]. For
analysis of N1 interactions with endogenous levels of Bcl-2 proteins,
cells were lysed in HEPES buffer [10 mM HEPES pH 7.4, 150 mM
NaCl, 1 mM EDTA, 1 % NP-40, 16 complete protease inhibitor
tablet (Roche)]. Lysates were centrifuged at 20 000 g for 15 min at
4 uC and cytosolic extracts were removed, pre-cleared with protein
A- or G-Sepharose beads for 1 h at 4 uC and incubated overnight at
4 uC with mouse monoclonal antibody HA.11 (Cambridge Biosciences)
or rabbit polyclonal antibodies to Bax, Bad (Cell Signaling
Technology), N1 or Bid (R&D Systems). Immune complexes were
bound to protein A– or G–Sepharose beads for 1 h at 4 uC,
washed four times in lysis buffer, eluted in 26 loading buffer and
boiled. Proteins were separated on NuPAGE Bis-Tris (12 % gel;
Invitrogen), transferred to PVDF membranes and blotted with
anti-HA.11, anti-N1, anti-a-tubulin (Upstate) or anti-Bcl-2 family
antibodies. Bound antibody was detected using horseradish
peroxidase (HRP)-conjugated anti-rabbit antibodies and visualized
using ECL Plus detection (Amersham Biosciences).
Apoptosis assays. HeLa cells were mock-infected or infected with
wild-type VACV (vN1), vDN1 or vN1-rev (Bartlett et al., 2002)
viruses at 2 p.f.u. per cell for 2 h, or transfected with pCI-based
expression vectors for N1, C40S mutant and Bcl-xL together with a
CD20 surface marker using Fugene 6 (Roche). Infected cells were
stimulated with 1 mM ST for 2 h or left untreated as indicated.
Transfected cells were selected using anti-CD20-coated magnetic
beads on a magnetic-activated cell sorter (MACS) column 24 h post-
transfection. Cells were replated in fresh medium, incubated for a
further 24 h at 37 uC and then stimulated with 1 mM ST for 4 h. Cell
lysates were tested for caspase 3/7 activity and caspase 3/PARP
cleavage using antibodies that detected the cleaved 17 (p17) and
89 kDa (p89) fragments, respectively, as described previously (Cooray
et al., 2003). Equivalent loading was verified by blotting for a-tubulin
(Upstate). Measurement of the change in mitochondrial potential
(Dym) was carried out using the potentiometric dye JC-1 as described
previously (Cossarizza et al., 1993). Briefly, cells were treated with
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ST, collected, washed in PBS and stained with 2 mM JC-1 dye
(Invitrogen) at 37 uC for 30 min. Cells were washed in PBS and
stained with anti-CD20 APC antibody (BD Pharmingen) for 20 min
on ice. Cells were then washed in PBS, resuspended in FACS buffer
[PBS with 2 % (v/v) FBS] and analysed by flow cytometry (FACScan;
Becton Dickinson).
Subcellular fractionation. Subcellular fractionation was carried out
as described previously (Seth et al., 2005). Briefly, HeLa cells were
mock-infected or infected with vN1 or vDN1 at 10 p.f.u. per cell for
6 h. Cells were washed with cold PBS and homogenized by douncing
20 times in 10 mM Tris/HCl pH 7.5, 2 mM MgCl2, 10 mM KCl,
250 mM sucrose, 0.5 mM DTT and protease inhibitor cocktail.
Nuclei were cleared from homogenates by centrifugation at 500 g for
10 min at 4 uC. Supernatants were then centrifuged at 5000 g for
10 min at 4 uC to collect crude mitochondria (M). Supernatants were
centrifuged at 15 000 g to separate cellular organelles/membranes (O)
and cytosol (C). Mitochondrial and organelle pellets were resus-
pended and rehomogenized in lysis buffer. Proteins were separated on
NuPAGE Bis-Tris (12 % gel; Invitrogen), transferred to PVDF
membranes and blotted with antibodies against N1, cytochrome c
(BD Biosciences) or Bcl-xL (Cell Signaling Technology). Specific
antibody binding was detected using an HRP-conjugated anti-rabbit
antibody and visualized using ECL Plus detection.
Protein expression and crystallization. The VACV N1L gene was
cloned into pET24a and expressed as a C-terminally His-tagged
protein as described previously (Bartlett et al., 2002). To prevent
protein aggregation and heterogeneity, a C40S mutation was
introduced using the QuikChange site-directed mutagenesis kit
(Stratagene), with primers N1LmutF 59-GGTAGATGACGGCGAT-
GTAAGCACATTGATTAAGAACTGAGA-39 and N1LmutR 59-TCT-
CATGTTCTTAATCAATGTGCTTACATCGCCGTCATCTACC-39.
Native and selenomethionine (Se-Met) proteins were expressed in
Escherichia coli B834(DE3). For Se-Met incorporation, a single colony
was grown overnight in 100 ml base medium (Molecular Dimen-
sions) containing 40 mg L-methionine l21. Bacteria were collected by
centrifugation, washed and used to inoculate a 1 l culture containing
40 mg L-selenomethionine l21. Cultures were grown to an absorbance
(A600) of 0.6 and protein expression was induced by the addition of
1 mM IPTG for 16 h at 20 uC.
The mutant N1 protein was purified by nickel-ion-affinity chroma-
tography and gel filtration on a Superdex75 column (Amersham
Biosciences). It was then concentrated to ~14 mg ml21 in 50 mM
Tris/HCl pH 8.5, 150 mM NaCl. Crystallization experiments were
performed using a Cartesian robot (Brown et al., 2003; Walter et al.,
2003). Crystals of N1 mutant were grown at 21 uC by vapour diffu-
sion in 100 nl+100 nl sitting drops equilibrated against 0.2 M Na/K
Table 1. Summary of crystallographic statistics; data collection, processing and refinement
Data collection and
processing
Peak Inflection Remote Native
X-ray source ESRF-BM14 ESRF-BM14 ESRF-BM14 ESRF-ID23EH1
Wavelength (A˚) 0.9789 0.9791 0.8856 0.9794
f’, f’’ 27.7, 5.6 29.6, 3.9 21.0, 4.0
Space group P21 P21 P21 P21
Unit cell [a, b, c (A˚); b (u)] 71.2, 110.1, 70.9; 109.8 71.2, 110.2, 70.9; 109.8 71.2, 110.2, 70.9; 109.8 71.7, 109.0, 70.1; 110.6
Resolution range (A˚)* 50.0–3.3 (3.4–3.3) 50.0–3.3 (3.4–3.3) 50.0–3.3 (3.4–3.3) 30.0–2.9 (3.0–2.9)
No. images 360 180 180 559
Unique reflections 14755 14679 14420 22319
Redundancy* 7.6 (7.5) 3.8 (3.8) 3.8 (3.9) 11.9 (11.4)
Completeness (%)* 92.1 (96.5) 91.2 (90.3) 90.2 (100.0) 100.0 (100.0)
I/s(I)* 22.5 (1.5) 12.4 (0.76) 20.5 (1.4) 17.9 (1.8)
Rmerge (%)*D 11.1 (93.6) 8.2 (–) 7.1 (67.7) 13.8 (–)
Refinement statistics Sixfold NCS constraints
Resolution range (A˚) 30.0–2.9
No. reflections (working/test) 21319/1094
Rfactord/Rfree§ 23.7/24.4
Rms D bond length (A˚) 0.014
Rms D bond angles (u) 1.6
Rms D main chain/side chain
B-factor (A˚2)
5.4/11.2
No. protein atoms per asym-
metric unit
5730
Mean protein B-factor (A˚2) 75
*Values in parentheses are for the outermost resolution range.
DRmerge5ShklSi|Ihkl;i–,Ihkl.|/ShklSiIhkl;i, where Ihkl;i is the intensity of an individual measurement and ,Ihkl.is the mean intensity from multiple
observations.
dRfactor5Shkl||Fobs|hkl2k|Fcalc|hkl|/Shkl|Fobs|hkl.
§Rfree equals the Rfactor against 5 % of the data removed prior to refinement.
Rms D, root-mean-square deviation from ideal geometry.
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phosphate, 0.2 M NaCl and 10 % PEG 8000, pH 6.2. Crystals
belonged to the space group P21 (a571.7 A˚, b5109.0 A˚, c570.1 A˚,
b5110.6 u) with six copies of N1 in the asymmetric unit (Table 1).
Data were collected at 100 K, using 20 % glycerol as the cryo-
protectant.
Structure determination. The structure of the N1 C40S mutant
protein was solved from a single Se-Met crystal by multiple
wavelength anomalous dispersion (MAD). MAD data were collected
at BM14 and higher resolution native data on ID23-EH1. Data were
processed and reduced using HKL2000 (Table 1) (Otwinowski &
Minor, 1997). The positions of the 42 selenium atoms in the
asymmetric unit were located and phases were calculated using
SOLVE (Terwilliger, 2000). Initial phases were improved by solvent
flattening and non-crystallographic symmetry (NCS) averaging using
RESOLVE (Terwilliger, 2000).The resulting electron density map
allowed a model to be built using COOT (Emsley & Cowtan, 2004).
The model was refined, imposing strict sixfold NCS constraints, using
CNS against the 2.9 A˚ resolution data (Bru¨nger et al., 1998).
Definition of side chains was improved by sharpening X-ray data with
a B-factor of 220 A˚2. Statistics for the final model are given in Table
1. The model has good stereochemistry and .98 % of residues are
within the most favourable regions of the Ramachandran plot (Davis
et al., 2004). Molecular representations were created using PyMOL
(www.pymol.org).
RESULTS AND DISCUSSION
Previously, when the N1 protein was overexpressed in
transfected cells it was found to inhibit activation of NF-kB
following stimulation by IL-1 or Toll-like receptor agonists
(DiPerna et al., 2004). Therefore, we extended these studies
by analysing if N1 could influence NF-kB-dependent gene
expression in VACV-infected cells, where N1 would be
expressed at natural levels. HeLa cells were transfected with
an NF-kB-responsive reporter gene and subsequently were
either mock-infected or infected with a wild-type VACV
(vN1), a recombinant VACV engineered to lack the N1L
gene (vDN1) or a revertant VACV (vN1-rev) in which the
N1L gene was reinserted into the deletion mutant at its
natural locus (Bartlett et al., 2002). Analysis of NF-kB gene
expression showed that in mock-infected cells the addition
of IL-1b increased gene expression six- to sevenfold, but
infection by all three viruses reduced this greatly and to a
similar extent (Fig. 1). Therefore, the loss of N1 was not
responsible for this virus-induced inhibition of NF-kB-
responsive gene expression. This might have been because
there are other NF-kB signalling inhibitors encoded by
VACV (Haga & Bowie, 2005) that mask a subtle influence
of N1 or because N1 exerts its profound effect on virulence
by other mechanisms. To address the latter possibility, we
investigated if N1 inhibited apoptosis.
N1 inhibits apoptosis
To examine whether N1 displays anti-apoptotic activity we
studied the cellular response to ST in cells transfected with
a plasmid expressing N1 and in cells infected with viruses
that do or do not express N1 (Methods). Transfection
efficiencies as determined by MACS and FACS were
between 30 and 50 %. Expression of either wild-type N1
or a mutant N1 protein with a C40S mutation (see below),
by transfection, inhibited the ST-induced increase in
mitochondrial membrane permeability (qDy) and caspase
3/7 activation (Fig. 2a, b). N1 was not as effective an
inhibitor as Bcl-xL possibly because N1 is a cytoplasmic
protein (Bartlett et al., 2002) whereas Bcl-xL and Bcl-2 are
targetted to mitochondria and the endoplasmic reticulum
(ER) (discussed below). Therefore, N1 may prevent
calcium release from the ER and mitochondrial apoptosis
less effectively (Foyouzi-Youssefi et al., 2000; Bassik et al.,
2004). Similarly, cells infected by a deletion mutant lacking
N1 (vDN1) (Bartlett et al., 2002) had reduced ability to
inhibit caspase 3/7 activity in response to ST (Fig. 3a)
compared with wild-type (vN1) and revertant (vN1-rev)
controls. Also cleavage of caspase 3 and PARP were more
rapid in vDN1-infected cells (Fig. 3b). However, compared
with mock-infected cells, vDN1-infected cells were still
resistant to ST-induced apoptosis, consistent with the
presence of other VACV apoptotic inhibitors (Taylor &
Barry, 2006). Subcellular fractionation revealed that in
vDN1-infected cells the proportion of cytochrome c in the
cytosol versus the mitochondria was increased compared
with mock-infected and vN1-infected controls (Fig. 3c).
Analysis of a-tubulin levels verified equal loading.
N1 binds to pro-apoptotic Bcl-2 family members
To address the mechanism by which N1 inhibits apoptosis,
we investigated if N1 might interact with pro-apoptotic
Bcl-2 family members. Cells were infected with vN1 or
vDN1 and extracts were immunoprecipitated with antibodies
Fig. 1. N1 does not inhibit IL-1-induced NF-kB-dependent gene
expression in VACV-infected cells. HeLa cells were transfected
with the NF-kB luciferase reporter, reseeded and mock-infected or
infected with VACV, vDN1 or vN1-rev at 2 p.f.u. per cell for 2 h.
Cells were then treated with 100 ng IL-1b ml”1 for 2 h and lysates
were assayed for luciferase activity. Data are expressed as the
mean fold induction compared to the mean of the normalized
luciferase activity in the mock infection. Data are means±SD.
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against Bad, Bax, Bid, Bak and Bim. Alternatively, cells were
transfected with plasmids expressing HA-tagged Bad, Bax or
control protein eiF4E, infected with vN1 or vDN1 viruses,
and immunoprecipitated with anti-HA or anti-N1 anti-
bodies. Immunoprecipitates were analysed by immunoblot-
ting with anti-N1 or anti-HA antibodies. N1 interacted with
endogenous levels of Bad, Bax and Bid (Fig. 4a), and also
with overexpressed Bad and Bax (Fig. 4b). An interaction
between N1 and endogenous Bak or Bim was not detected
(data not shown). A possible structural explanation for this
selectivity is discussed below.
Determination of N1 structure
To investigate how N1 was able to inhibit apoptosis and bind
pro-apoptotic Bcl-2 family members, its crystal structure was
determined. The full-length wild-type N1 and a C40S mutant
Fig. 2. N1 inhibits ST-induced apoptosis in transfected HeLa
cells. HeLa cells were transfected with vectors expressing N1,
C40S, Bcl-xL or empty control vector (pCI) together with a cell
surface CD20 expression vector. After 24 h, transfected cells
were selected on MACS columns using anti-CD20-coated
magnetic beads as described in Methods and replated into culture
medium. After a further 24 h, cells were treated with 1 mM ST
(black bars) for 4 h or left untreated (white bars) and assayed for
caspase activity (a) and mitochondrial dysfunction (b) as described
in Methods. Bcl-xL and Bcl-2 (not shown) were used as positive
controls. Asterisks indicate significant difference compared with
pCI+ST samples. Data are means±SD (*P,0.05, **P,0.005;
Student’s t-test, n53).
Fig. 3. N1 inhibits ST-induced apoptosis in VACV-infected cells.
HeLa cells were mock-infected or infected with vN1, vDN1 or vN1-
rev at 2 p.f.u. per cell for 2 h followed by treatment with (black
bars) or without (white bars) 1 mM ST for 2 h (panel a) or the
indicated times (panel b), and were assayed for caspase activity
(a), and caspase-3 (p17 fragment) and PARP (p89 fragment)
cleavage (b). (c) HeLa cells were mock-infected or infected with
vN1 or vDN1 at 10 p.f.u. per cell for 6 h and mitochondrial (M),
organelle (O) and cytosolic (C) fractions were isolated by
subcellular fractionation. Fractions were analysed by immunoblot-
ting for N1, cytochrome c, a-tubulin and Bcl-xL. Data are
means±SD (**/##P,0.005, ***P,0.0005; Student’s t-test,
n53). Blots are representative of three individual experiments.
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were expressed in E. coli, purified, crystallized and the
structure was solved at 2.9 A˚ resolution by MAD analysis of
the selenomethionated protein (Methods and Table 1). The
C40S mutation was introduced to avoid intermolecular
disulphide bond driven aggregation. The crystal contains
three dimers per asymmetric unit. The structural model
encompasses residues 1–114 (residues 115–7 were not visible
in the electron density map) and has an Rfactor/Rfree of 23.7/
24.4 %. The structure of the dimer is shown in Fig. 5(a). Note
that the C40S substitution is distal to the dimer interface.
The overall topology of N1 is similar to Bcl-xL
N1 contains seven a-helices (Fig. 5b) arranged with a fold
similar to Bcl-xL (Fig. 5c) (Muchmore et al., 1996) and
other Bcl-2 family members (Chou et al., 1999; Suzuki
et al., 2000; Petros et al., 2001; Hinds et al., 2003; Day et al.,
2005), including viral counterparts (Huang et al., 2002,
2003; Polster et al., 2004; Loh et al., 2005). Helix a5 forms
the hydrophobic core of the structure and is surrounded
by the other helices. Comparison of N1 with Bcl-xL using
program SHP (Stuart et al., 1979) matched 96 Cas out of
114 with root-mean-square deviation (rmsd) 2.4 A˚, and
revealed secondary structure elements representing the BH
motifs of Bcl-2 family members equivalent to those in Bcl-
xL (Fig. 5d). These similarities were not apparent from
sequence alignments. Although the overall fold of Bcl-2
family members is conserved, there are notable differences
mainly in the relative lengths of the helices and connecting
loops. The a1–a2 loop of N1 is considerably shorter (8
residues) than in Bcl-xL (63 residues), a feature shared with
other viral Bcl-2 counterparts (Huang et al., 2003; Polster
et al., 2004; Loh et al., 2005). In cellular Bcl-2 family
members, this loop contains sites for caspase cleavage and
phosphorylation (Polster et al., 2004), which converts anti-
apoptotic Bcl-2 proteins into pro-apoptotic molecules.
This structural alteration is an example of how viral
proteins have evolved to circumvent cellular regulatory
mechanisms. Other differences include the positions of
helices a3 and a4, which lie roughly anti-parallel in the
Fig. 4. N1 interacts with Bad, Bax and Bid.
Endogenous Bax, Bid and Bad (a) or over-
expressed HA-tagged Bax, Bad or eiF4E
control protein (b) were immunoprecipitated
from lysates of HeLa cells infected with wild-
type VACV (vN1) or N1 deletion virus (vDN1).
The input lysates and immunoprecipitates (IP)
were fractionated by SDS-PAGE and immuno-
blotted for a-tubulin, N1, HA or Bax, Bid and
Bad (Methods).
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ligand-free structure of Bcl-xL, but are almost orthogonal
in N1. This change affects the surface topology of N1,
producing a groove, which is discussed below. Bcl-xL
contains a longer a5 helix and shorter a5–a6 loop than N1.
Furthermore, a6 runs into an extra helix in Bcl-xL, whilst in
N1 the structure is shortened, a compact loop enabling
interaction between a6 and a7. The C-terminal hydro-
phobic a-helix of Bcl-xL, Bcl-w and Bax localizes these
Bcl-2 proteins to mitochondria where they regulate the
permeability of the outer mitochondrial membrane
(Martinou & Green, 2001), and prevention of calcium
release from the ER (Foyouzi-Youssefi et al., 2000; Bassik
et al., 2004). This helix is lacking in N1 and, consistent with
this, N1 is cytosolic (Bartlett et al., 2002) and does not
change location after pro-apoptotic stimulation or co-
localize with mitochondria in apoptotic cells (data not
shown).
Properties of the N1 BH3-binding groove and
dimer interface
The predominantly acidic surface of N1 (Fig. 6a) contains a
surface groove formed by helices a2, a3, a4 and the N
terminus of a5 (Fig. 5b). In anti-apoptotic Bcl-2 family
members, corresponding hydrophobic grooves serve as
binding sites for the BH3 motifs of pro-apoptotic members
(Sattler et al., 1997; Petros et al., 2000; Liu et al., 2003). For
Bcl-xL, unbound and peptide bound structures (Liu et al.,
2003) reveal that on peptide binding helix a3 is displaced,
opening the groove to accommodate the peptide (Fig. 5c).
In contrast, the N1 groove has an open conformation that
could readily bind BH3 regions of pro-apoptotic Bcl-2
proteins. Notably, N1 superimposes better on the Bcl-xL–
Bim open-groove conformation (rmsd 2.4 A˚) than the
unbound closed-groove conformation (rmsd 2.8 A˚). In
Fig. 5. The structure of N1. (a) The dimer of N1 is viewed looking along the molecular twofold axis. BH1, BH2, BH3 and BH4
motifs are coloured green, magenta, yellow and blue, respectively and N and C termini are labelled. The right hand view is the
same as in (b) and looks onto the surface groove and the mutated C40S residue is shown in red. For clarity, the helices of one
monomer have been labelled. In the crystal structure of N1, the asymmetric unit has three dimers, each held together by anti-
parallel interactions between helix a1 and a6 of each subunit, with a loss of 950 A˚2 of solvent accessible surface. The interface
does not involve the surface groove, which consequently is exposed and available to bind BH3 motifs. (b and c) Comparison of
the structure of VACV N1 with Bcl-xL. Cartoons of N1 (b) and Bcl-xL (c), with structurally equivalent BH1, BH2, BH3 and BH4
motifs coloured as in panel (a). The position adopted by helix 3 of Bcl-xL when complexed with the Bim BH3 helix is drawn as a
red semi-transparent loop and red arrows show movement of this helix upon peptide binding. (d) Sequence alignment of N1 and
Bcl-xL based on structural alignment from SHP (Stuart et al., 1979). The core of the molecules, used in the structure based
alignment, are highlighted in pink. Strictly conserved residues are in red blocks and similar residues in blue boxes. Secondary
structural elements are coloured by BH motif definition, as above. To avoid breaking up the VACV N1 sequence, residues for
Bcl-xL that are not matched by N1 are omitted, and the position and number of residues removed are indicated under the Bcl-xL
sequence. The position of a disordered loop in Bcl-xL is marked by the green triangle.
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Bcl-xL, residues from the BH1, BH2 and BH3 motifs are
crucial for binding peptides from Bad (Petros et al., 2000),
Bak (Sattler et al., 1997) and Bim (Liu et al., 2003), usually
by forming hydrophobic pockets in the groove. In N1, two
of these hydrophobic residues (L27 and L42, located in a2
and a3) are conserved (Bcl-xL residues L90 and L108,
respectively), some others are similar (L30–A93, L33–F97,
V39–F105, I66–W137 and I75–F146; the first residue in
each pair is that of N1), whereas others are charged (D38–
A104, R58–V126, K70–V141 and R71–A142). Overall, the
N1 groove is distinguished by these charged residues (Fig.
6a–c) and by the absence of the characteristic NWGR
sequence found at the N terminus of a5 in other Bcl-2
structures (Petros et al., 2004) [whilst the N is conserved
(N65) and W is replaced by the chemically similar I66, the
GR pair are replaced by acidic residues E67 and D68, Fig.
5d]. These changes suggest that contacts between the N1
groove and BH3 ligands would differ from the paradigm
provided by the Bcl-xL–Bim peptide complex (Liu et al.,
2003). Residues I, L, I and F at points 1, 5, 8 and 12 in the
BH3 motif (Figs 6d, 7) provide key anchor points in the
hydrophobic Bcl-xL pockets (Figs 6b, 7). These anchors
Fig. 6. Comparison of N1 and Bcl-xL surface grooves and molecular modelling of BH3 peptides. Molecular surfaces of N1 (a)
and Bcl-xL (b), with the grooves highlighted. Lys, Arg and His are coloured in blue, Asp and Glu are coloured in red and Leu, Ile,
Val, Met, Tyr, Phe and Trp are coloured in yellow. All other residue types are coloured in grey. (c) Molecular surface of N1 with
the Bim BH3 helix (PDB code 1PQ1) modelled into the surface groove as described in the text. The surface of N1 is coloured
as described in (a). The peptide is coloured from cyan to magenta from the N to the C terminus. The middle panel shows the
Bim peptide from residue 85 to 105 with contacting residues drawn in atomic detail. Residues of the peptide contacting N1 are
labelled in black and residues of N1 contacting the peptide are labelled in white. The lower panel shows the Bim BH3 peptide
helix skeleton coloured from cyan to magenta, with the contacting residues of Bcl-xL and their equivalents of N1 boxed (N1
residues are in parentheses), and residues coloured according to their properties, as in (a). (d) Helical wheel representation of
the Bim BH3 peptide (residues 85–105), drawn rotating the peptide in (c) by 90 6 around an axis vertical to the page, showing
the predominantly amphipathic nature of the BH3 helix.
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appear generic; similar hydrophobic residues being used in
binding to Bak and Bad peptides (Sattler et al., 1997; Petros
et al., 2000) (position 5 is strictly conserved).
The dimers of N1 observed in the crystal structure are held
together by anti-parallel interactions between a1 and a6 (Fig.
5a). The constitutively open hydrophobic surface grooves
are distal to this dimer interface, allowing the dimer to
readily bind BH3 motifs of pro-apoptotic proteins. The N1
dimer interface differs markedly from the only other dimeric
Bcl-2 protein reported, for Bcl-xL, which shows a domain-
swapped dimeric association via the loop connecting a5 and
a6 (O’Neill et al., 2006). In the N1 dimer, no such domain
exchange exists. The ability of N1 to function as a
homodimer (Bartlett et al., 2002) suggests that it might
bind to two pro-apoptotic Bcl-2s simultaneously.
Charged residues in the N1-binding groove may
contribute to BH3-binding specificity
To investigate if N1 might bind BH3 peptides, we first
modelled Bad, Bak and Bim peptides into the N1 groove.
Structural superposition (Stuart et al., 1979) of N1 and the
mouse Bcl-xL–Bim complex positioned the Bim peptide into
the N1 groove. The Bad and Bak peptides were then
superposed on Bim. This modelling procedure resulted in
minor steric clashes between the peptides and the groove (e.g.
R71 with G98 of the Bim peptide) that could be relieved by
slight rearrangements. In each model, the central portion of
the groove is occupied by the core sequence motif of the
peptides representing the conserved BH3 motif (Fig. 6c).
However, the pockets that locate the hydrophobic anchor
residues (which are entirely hydrophobic in Bcl-xL) are, in
N1, lined by both hydrophobic and charged residues (for
instance D38, V39, R71 and I75 for the L94 pocket, Fig. 6c). As
the N1 groove is constitutively open, such changes may be a
strategy to avoid the unfavourable thermodynamic conse-
quences of exposed hydrophobic patches on the protein
surface. Collectively, these observations predict that N1 might
bind the pro-apoptotic Bcl-2 proteins via their BH3 motifs,
consistent with the biochemical data presented above (Fig. 4).
Furthermore, the BH3 motifs of the pro-apoptotic Bcl-2
proteins Bad, Bax and Bid are markedly less hydrophobic
than those of Bak, Bim and Hrk due to differences in the
residues flanking the core BH3 motif (Fig. 7). This difference
might explain why interactions between N1 and endogenous
Bad, Bax and Bid, but not Bak or Bim were detected by
immunoprecipitation. In contrast, in vitro binding of N1 to
BH3 peptides from Bid, Bim and Bak, but not Bad, was
reported by Aoyagi et al. (2007), but these interactions were
not confirmed by analysis of whole proteins. These differences
may reflect the different methods used. It is possible that, like
N1, cellular Bcl-2 proteins also achieve selectivity by sensing
the sequence of BH3 motif flanking regions.
Conclusions
Functional analysis demonstrates that N1 inhibits apoptosis
both in transfected cells and in VACV-infected cells and,
consistent with this, biochemical analysis shows that N1
binds pro-apoptotic Bcl-2 family proteins Bad, Bax and Bid.
The crystal structure of N1 reveals that it is a dimeric Bcl-2-
like protein with a surface groove that is constitutively open
and that is predicted by molecular modelling to bind BH3
motif peptides of pro-apoptotic Bcl-2 family members. The
surface groove also indicates how N1 might bind BH3
peptides selectively, and this has implications for cellular
Bcl-2 protein interactions. The lack of significant sequence
similarity between N1 and other Bcl-2 family proteins
suggests that retention of the structure is a result of strong
evolutionary pressure, and underlines the importance of
structural information in understanding the molecular
functions of proteins. It remains possible that other viral
or cellular Bcl-2 family proteins exist that will only be
identified through structural analysis. N1 is the first VACV
protein shown to be a Bcl-2 family member and represents
another example of VACV anti-apoptotic proteins.
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